jCell Market Sales

Key Factors Driving jCell Growth

1. Regenerative cell therapy with disease-modifying potential

• jCell consists of retinal progenitor cells (RPCs) delivered via intravitreal injection to support retinal repair and photoreceptor survival.
• Mechanism includes:
  • Neurotrophic support
  • Preservation of existing photoreceptors

2. Gene-agnostic approach (broad applicability)

• jCell is not genotype-specific, meaning it can treat RP patients regardless of underlying mutation.

 

3. Positive clinical signals (Phase I/II and Phase IIb)

• Phase I/II study (n=28):
  • Well tolerated with no serious safety issues
• Dose-dependent improvement in visual acuity:
  • § Up to +9 letter gain at highest dose
• Phase IIb randomized trial:
  • Demonstrated restoration of visual function vs sham
  • Better outcomes in patients with preserved central visual field

 

4. Favorable safety and ease of administration

• Delivered via intravitreal injection (non-surgical)
• No requirement for immunosuppression
• Mostly mild to moderate adverse events reported

 

5. Large unmet need in retinitis pigmentosa

• RP affects:
  • ~2 million people globally (~100,000 in the US)
  • Most patients lack effective treatment options

 

6. Advancement toward late-stage development

• Ongoing clinical program (e.g., JC02-88 study) evaluating higher doses
• Designed to:
  • Optimize efficacy
  • Support registrational pathway

 

jCell Recent Developments

• In August 2025, jCyte announced the publication “Retinal Progenitor Cells (jCell) for Retinitis Pigmentosa” containing results from its Phase I/IIa clinical trial evaluating the safety and tolerability of intravitreal injection of retinal progenitor cells (RPCs) in adults with non-syndromic retinitis pigmentosa (RP).  

“jCell Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of jCell for potential indication like Retinitis pigmentosa and Diabetic retinopathy in the 7MM. A detailed picture of jCell’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the jCell for potential indications. The jCell market report provides insights about jCell’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current jCell performance, future market assessments inclusive of the jCell market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of jCell sales forecasts, along with factors driving its market.

 

jCell Drug Summary

jCell is an investigational, allogeneic cell-based therapy developed by jCyte for the treatment of degenerative retinal diseases such as retinitis pigmentosa. The therapy consists of human retinal progenitor cells (hRPCs) delivered via intravitreal injection, designed to preserve and enhance the function of remaining photoreceptors rather than replace them. jCell works primarily through paracrine mechanisms, secreting neurotrophic factors that support photoreceptor survival, reduce apoptosis, and potentially improve retinal function. Unlike gene-specific therapies, jCell is mutation-agnostic and may benefit a broad range of patients regardless of the underlying genetic cause. Clinical studies have demonstrated improvements in visual acuity and functional vision in some patients, supporting its continued development as a regenerative treatment aimed at slowing disease progression and preserving sight in inherited retinal disorders. The report provides jCell’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

 

Scope of the jCell Market Report

The report provides insights into:

• A comprehensive product overview including the jCell MoA, description, dosage and administration, research and development activities in potential indication like Retinitis pigmentosa and Diabetic retinopathy.
• Elaborated details on jCell regulatory milestones and other development activities have been provided in jCell market report.
• The report also highlights jCell‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The jCell market report also covers the patents information, generic entry and impact on cost cut.
• The jCell market report contains current and forecasted jCell sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The jCell market report also features the SWOT analysis with analyst views for jCell in potential indications.

 

Methodology

The jCell market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

 

jCell Analytical Perspective by DelveInsight

In-depth jCell Market Assessment

This jCell sales market forecast report provides a detailed market assessment of jCell for potential indication like Retinitis pigmentosa and Diabetic retinopathy in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted jCell sales data uptil 2034.

 

jCell Clinical Assessment

The jCell market report provides the clinical trials information of jCell for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

jCell Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

 

jCell Market Potential & Revenue Forecast

• Projected market size for the jCell and its key indications
• Estimated jCell sales potential (jCell peak sales forecasts)
• jCell Pricing strategies and reimbursement landscape

 

jCell Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• jCell Market positioning compared to existing treatments
• jCell Strengths & weaknesses relative to competitors

 

jCell Regulatory & Commercial Milestones

• jCell Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

 

jCell Clinical Differentiation

• jCell Efficacy & safety advantages over existing drugs
• jCell Unique selling points

 

jCell Market Report Highlights

• In the coming years, the jCell market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The jCell companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence jCell’s dominance.
• Other emerging products for Retinitis pigmentosa and Diabetic retinopathy are expected to give tough market competition to jCell and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of jCell in potential indications.
• Analyse jCell cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted jCell sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of jCell in potential indications.

Key Questions Answered In The jCell Market Report

• What is the class of therapy, route of administration and mechanism of action of jCell? How strong is jCell’s clinical and commercial performance?
• What is jCell’s clinical trial status in each individual indications such as Retinitis pigmentosa and Diabetic retinopathy and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the jCell Manufacturers?
• What are the key designations that have been granted to jCell for potential indications? How are they going to impact jCell’s penetration in various geographies?
• What is the current and forecasted jCell market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of jCell in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan? 
• What are the other emerging products available and how are these giving competition to jCell for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is jCell? What is the duration of therapy and what are the geographical variations in cost per patient?